Abstract Background An emerging class of new protease-activatable prodrugs designed to enhance on-target activity and reduce off-target toxicity are being actively developed. Cytokines […]
Abstract Recombinant IL-2 (aldesleukin) is a potent T cell proliferation and differentiation factor and is an approved immunotherapy for advanced melanoma and renal […]
